OTC M&A Trend May Be Result Of Too Many Large Players At The Top – Panel
This article was originally published in The Tan Sheet
A lack of competitive global scale may be one factor fueling the divestiture of OTC units by larger pharma companies
You may also be interested in...
Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.
Bayer expects the addition of Roche Consumer Health to bolster the firm's ability to handle future Rx-to-OTC switches
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC